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Original Article
Towards ‘Engagement 2.0’: Insights from a study
of dynamic consent with biobank participants
Harriet JA Teare1, Michael Morrison1, Edgar A Whitley2 and Jane Kaye1
Abstract
Web 2.0 technologies have enabled new methods of engagement, moving from static mono-directional sources of infor-
mation to interactive user-led experiences. Use of Web 2.0 technologies for engagement is gaining momentum within the
health sector however this is still in its infancy in biobanking research. This paper reports on findings from focus groups
with biobank participants to gauge their views on a Web 2.0 dynamic consent interface. The findings from this study suggest
that participants would welcome more interactive engagement with biobanks, and the opportunity to hear more about how
their data and samples are being used in research. We propose that by adopting Web 2.0 tools for dynamic consent, we can
move towards an ‘Engagement 2.0’ model whereby research participants have the opportunity for more interactive engage-
ment with medical research, setting up a two-way communication channel between participants and researchers, for the
benefit of both.
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Introduction
The advent of the World Wide Web and the subsequent
development of Web 2.0 technologies has enabled new
methods of engagement.1 Web 2.0 has been described
as ‘second generation of the World Wide Web that is
focused on the ability for people to collaborate and
share information online [. . .] with an emphasis on
web-based communities of users, and more open shar-
ing of information’.2 This transition from a Web 1.0
approach to a more interactive, Web 2.0 user-led
experience is gaining greater momentum within the
health sector, particularly within clinical care where
these technologies have been used to engage patients.
However, adoption has been slower in medical research
and in the ﬁeld of biobanking, where using Web 2.0 to
engage with participants is still in its infancy.
This paper reports on ﬁndings from a series of focus
groups with biobank participants to gauge their views
on a Web 2.0 dynamic consent interface. Dynamic con-
sent is designed to enable biobank participants to revi-
sit consent choices and have a more active involvement
with the research of the biobank. The aims of this study
were therefore to understand biobank participants’
current experience of biobanking, and to determine
whether a Web 2.0 interface such as dynamic consent
would be welcomed as a tool to help participants better
engage with the research activities of the biobank. The
paper begins by describing the way that research par-
ticipation in biobanking is currently carried out, and
reviews previous empirical studies to contextualise our
ﬁndings. We then present the details of our empirical
study with participants of three biobanks in the UK.
The ﬁndings from the study suggest that the partici-
pants we studied would welcome a more interactive
engagement with the biobanks. In the ﬁnal section of
this paper, we discuss what the features of an
‘Engagement 2.0’ approach might be, when applied to
biobanking research.
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Biobanking participation
As biobanks are increasingly being used as a resource
for medical research, they are inﬂuencing the way we
view the role of research participants, the nature of
their participation and the ways in which engagement
might occur. Biobank governance mechanisms such as
consent have been adapted from conventional models
of engaging with research participants. This approach
can be considered ‘Engagement 1.0’. It typically relies
on paper-based information and interactions with
healthcare staﬀ. However the function of biobanks as
research resources calls into question traditional forms
of consent, as well as processes and practices for
recruitment, participation and engagement. In clinical
research, crucial elements of research recruitment typ-
ically include signing a paper consent form and obtain-
ing information either directly from healthcare staﬀ, or
through reading leaﬂets or paper-based information
sheets. This method of communication is enabled by
regular face-to-face interactions through the clinic.
However, because there are fewer clinical interactions
in biobanking, there are fewer possibilities to engage
with participants, with participation and engagement
practices largely concentrated at the start of the pro-
cess, at the point of recruitment and sample collection
as the only face-to-face interactions.
Biobank research therefore involves a more abstract
understanding of participation. Here, the participant is
approached during their clinical care, or responds to an
advert for healthy participants, agrees to enrol with the
biobank, signs a consent form and provides samples and
data. These are stored in the biobank for future research
use, and unless further samples or data are required at a
later date, this signiﬁes the end of the participant’s active
involvement with the biobank and the associated
research studies. As participants often give a broad con-
sent to allow for use of samples in unspeciﬁed future
research,3 there is no need to go back to them for a
new consent when a new study using the biobank collec-
tion commences. The role of biobank participants there-
fore becomes a passive one after the initial enrolment
and sample collection. Nevertheless participants’ sam-
ples and data are still involved in research as they may
be accessed, tested and used in projects for many years
after the initial enrolment.
One dilemma for biobanks is the extent to which
their activities can be considered transparent in the
absence of ongoing participation and engagement
with biobank participants. Relying on a broad consent
heightens this dilemma. For example, the controversy
that surrounded the Icelandic population biobank in
2000 has demonstrated the importance of public
trust.4 To improve transparency and help develop
accountability, and thus demonstrate trustworthiness,
some biobanks have developed innovative ways to
inform and involve participants beyond the initial
face-to-face recruitment.5,6 While such initiatives are
important, any mono-directional information ﬂows
(newsletters, websites) follow a ‘1.0’ approach. Other
forms of engagement may also be limited to participant
representatives rather than the whole cohort. Web 2.0
engagement for biobanks would need to move towards
more interactive dialogues that potentially could enable
participants to interact with the research team, to pro-
vide new consents when required as well as being able
to receive regular updates on the research conducted on
the biobank. This should not simply be viewed as an
update in the use of technology, but as an overhaul of
the philosophy behind participation and the role of par-
ticipants in biobanking research, contributing to the
growing belief that participants are research partners,
not passive subjects. The potential to address the con-
cerns about broad consent, the passive nature of bio-
bank participation and concerns about maintaining
public trust were the impetus for the Web 2.0 dynamic
consent study.
Empirical studies in biobanking
Several empirical studies have sought to establish the
views of research participants on various aspects of
these challenges faced by biobanks. There is a consid-
erable body of empirical work on engaging patients and
publics in biobanking research.7,8 This includes studies
designed to gauge the attitudes of various publics to
biobanking projects,911 and research on the views
and motivations of actual and potential biobank par-
ticipants.1216 Studies have also addressed key concerns
such as broad consent, trust, reciprocity and the use of
Web 2.0 technology.
A number of recent large-scale studies investigating
prospective consent preferences (e.g. broad versus trad-
itional informed consent) among non-patient adults in
Scotland,17 and the US reported a preference amongst
respondents for a single, one-oﬀ, consent at the time of
donation (eﬀectively a broad consent since future uses
cannot be foreseen).18,19 In a meta-analysis of the quan-
titative and qualitative sociological literature on public
and patient attitudes to biobanking Lipworth et al.
reached a similar conclusion;7 that ‘few people
demanded recurrent, project-speciﬁc consent and few
wished to place limits on the uses to which their
tissue could be put’.
Care must be taken, however, when evaluating these
results. For several studies, while a statistically signiﬁ-
cant preference for one form of consent over another
can be detected this is not necessarily indicative of a
clear majority preference.17 In the case of prospective
‘public attitude’ surveys on biobanking, of which the
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existing literature contains a prevalence,7 Johnsson
et al. found that reported willingness to share data
and tissue for research was prone to both overestimat-
ing and underestimating recorded participation levels in
diﬀerent cases which limits its predictive power.20
Many of these studies focus on the initial engage-
ment with biobanks, including investigating the condi-
tions under which biobanks and participation in
biobanking studies can secure social legitimacy.21 This
is often expressed in terms of ‘public trust’. Although a
detailed review of the diﬀerent conceptions of ‘trust’
mobilised in diﬀerent studies is beyond the scope of
this paper, trust is widely regarded as a critical factor
in ensuring the viability of biomedical research,22 and
has been found to vary in relation to levels of public
trust in national governments, types of institutions
involved in biobanking,7,10,23 diﬀerent social and pro-
fessional groups and a range of individual and group
characteristics including whether people are healthy
volunteers or patient donors.7,8,15,16 A related strand
of scholarly inquiry also examines diﬀerent governance
models for emerging biobanks as a way to test the
‘public appeal’ of diﬀerent options,17 and as sites for
community engagement through deliberative democ-
racy approaches.5,24,25
Recent studies have identiﬁed key elements that can
facilitate trustworthiness. Participants are more trust-
ing if they are recruited by a healthcare professional
and there is ongoing engagement.26,27 Eﬀective engage-
ment therefore needs to be substantive, valued by all
parties and involve an ongoing relationship.28
Watanabe et al. identify ongoing communication as
an important part of an engagement strategy and for
sustaining trust between participants and biobanks.29
Some biobanks, such as UK Biobank and the
Norwegian Mother Child Cohort Study provide regu-
lar updates to participants, but it is unclear how wide-
spread such communication practices are and what
form they take (mono or bi-directional), how valued
they are by participants and which approaches are par-
ticularly eﬀective. Known examples are largely Web
1.0, and it is thus recognised that:
[T]he vast repertoire of Web 2.0, from YouTube to
social media, still remains to be integrated and used
by many biobanks, whose communications eﬀorts are
all too often limited to rather self-contained web pages
that are sorely lacking in interactive features that could
engage people.11
Recent studies into the attitudes of biobank partici-
pants have addressed the issue of reciprocity as another
feature of the engagement process. Nobile et al. argue
that two kinds of reciprocity can be identiﬁed in par-
ticipant accounts of reasons for participation in
biobank studies: ‘altruistic reciprocity’ where partici-
pants reported a desire to ‘give something back’ in
return for past medical care and a more ‘self-interested’
reciprocity where participants also expect to receive
something of beneﬁt to them in return for giving their
samples and data to a biobank.16 The latter form of
reciprocity is similar to the idea that for many partici-
pants, sharing samples and data with a biobank is a
‘conditional gift’, which is freely given but with an
expectation of particular behaviours and actions by
the recipient, identiﬁed by Hobbs et al.14
The link between reciprocity and engagement
becomes clearer when some examples of reciprocity
from biobanks that participants have requested/
received include feedback of information on how their
samples have been used in research, feedback of general
research ﬁndings, agreement that ﬁndings will be made
available to the wider scientiﬁc community, agreement
that research results, samples, data, etc. will remain in
the public sphere and not be privatised, and the return
of personal health information.9,13,14,16
The dynamic consent study
The concept of dynamic consent (DC) grew out of the
EnCoRe project (20082012), which aimed to investigate
the viability of electronically-mediated ﬂexible manage-
ment of consent and personal data across a range of set-
tings, including biobanking.30 In the biobank context, the
DC interface connects participants to the biobank(s) to
which they have donated material and data. It is intended
to make biobanking more participant-centred by making
it more dynamic and more interactive.31 The DC interface
can act as a mechanism for obtaining consent for new
research carried out on the biobank; providing more
information about biobanking and research in a range
of accessible formats as well as feeding information
back to participants, from a ‘thank you’ message upon
donation, to outcomes of particular studies and poten-
tially even health-related ﬁndings.32 It allows participants
to set (and alter) their preferences, both in terms of con-
sent and the level, frequency and type of communication
they wish to receive from the biobank studies in which
they are involved. Importantly, a DC system does not
mandate ongoing involvement. Participants can choose,
for example, to give, eﬀectively, a broad consent with little
further contact if that is their preference, but unlike
paper-based consent systems they retain the option to
revise this choice at a later date. This approach is increas-
ingly being tested in research projects.33
Study design
The purpose of this empirical study was to determine
(1) biobank participants’ current experience of
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biobanking, and (2) whether a Web 2.0 DC interface
would be welcomed as a tool to engage with the bio-
bank. Donating blood and/or tissue samples to bio-
bank research is not yet a commonplace occurrence.
The ‘general lay public’ was not therefore considered
a suitable audience to evaluate and give feedback on the
usefulness, relevance and accessibility of DC. The study
design sought to obtain feedback from individuals for
whom donation was a relatable experience, including
biobank donors with diﬀerent medical conditions as
well as healthy volunteers to incorporate a range of
experiences and motivations for donation.7,34
Recruitment
The recruitment and all subsequent empirical work
were carried out between January and May 2013.
Participants were recruited from three biobanks (see
Table 1 for details). Each biobank had a diﬀerent
research focus. Participants recruited from Biobanks 1
and 3 were, or had been patients with musculoskeletal
disorders and sarcoma respectively. Biobank 2 pro-
vided participants from a cohort of healthy volunteers.
This approach had the beneﬁt of providing a list of
prospective participants in the form of known tissue
donors across a range of conditions and with reliable
contact details. In addition all three banks were gov-
erned by the same NHS Hospital Trust. Research
Ethics Committee (REC) approval from the NRES
Committee West Midlands  South Birmingham to
carry out interviews in the jurisdiction of this Trust
had already been obtained as part of the EnCoRe pro-
ject (see Whitley et al. for details),35 and permission was
successfully sought to extend this approval to cover
additional focus groups.
Participants from each biobank were recruited by
letters, accompanied by a participant information
sheet (PIS) inviting them to discuss their experiences
and give feedback on the DC interface. An additional
leaﬂet provided information about DC. As the details
of each biobank’s donor list are conﬁdential, the
invitation letter and PIS were prepared by the research
team, and sent by the biobank staﬀ. Biobanks 1 and 2
had previous experience of sending out surveys and
questionnaires to their donor populations and, based
on this, predicted an expected response rate of 10%.
Each group sent out 300 invitation packs with the
intention of recruiting 30 participants from each
biobank.
With Biobank 3, the particularly fraught, ongoing
nature of sarcoma treatment meant that additional con-
cerns needed to be met in participant recruitment.
Letters were targeted exclusively to individuals who
the lead clinical research nurse deemed to be at an
appropriate stage in their treatment where their partici-
pation would not cause undue physical or emotional
stress. Fifty carefully targeted letters were sent to
potential participants from Biobank 3. In addition,
the lead clinicians involved requested that the clinical
research nurse be present during all interactions with
patients to respond to any medical questions the par-
ticipants might have. Response rates were relatively low
for all three biobanks (ranging from 312% across the
groups) (see Table 2 for details).
Focus groups
Focus groups were the preferred method of data collec-
tion. Focus groups can be understood as organised dis-
cussions that emphasise communication between
research participants in order to generate data based
on group interaction.36,37 As a consequence they are
particularly useful for revealing diﬀerent perspectives,
beliefs and attitudes, for example when one person’s
contribution triggers responses from other partici-
pants.36,38 Despite the low levels of response, it was
possible to organise participants from Biobank 1 into
three focus group sessions with a further two sessions
for participants from Biobank 2. For Biobank 3 it did
not prove possible to agree a date and time when all
respondents were available. It was considered undesir-
able to mix individuals from Biobank 3 into other focus
Table 1. Characteristics of biobanks involved.
Biobank History Disease focus Type of participants recruited Tissue type
1 Established Musculo-skeletal
diseases
Adults with current or prior
musculo-skeletal disease
Tissue samples removed during surgery to
repair or replace damaged hip, knee,
ligament or tendon
2 Established Diabetes Adult healthy volunteers Healthy tissue samples for use as controls
3 Recently converted
from tissue collection to a
biobank
Cancer Adults with a specific cancer
sub-type
Tumour tissue removed during surgery
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groups as their particular experiences would possibly be
lost in the group discussion. Instead it was preferable to
hold one small focus group with three Biobank 3 par-
ticipants and conduct two additional interviews with
the other one and two (related) respondents respect-
ively. Although focus groups were the preferred
method because of their particular advantages, we
decided it was better, and more ethically appropriate,
to allow patients who wanted to contribute to do so
even if enabling their contribution meant using a diﬀer-
ent method of data collection. To maximise the com-
parability of data across focus groups and interviews
the same set of prompting questions and the same pro-
cedures were employed for both focus groups and inter-
views. For the purposes of data analysis and
interpretation the information from the two interviews
was treated as a set of additional contributions to the
single Biobank 3 focus group.
To facilitate the focus groups a three-person research
team was present; one member to act as a mediator, a
second to act as a note-taker and the remaining person
to monitor the recording device. The focus group dis-
cussion was divided into two parts. In the ﬁrst part, the
aim was to clarify how participants understood their
existing relationship with their biobank. The mediator
asked each group a set of introductory questions about
participants’ experiences of giving consent and back-
ground information. This encouraged interaction
among group members, with the mediator responsible
for standardising the questions for each group, and
including less responsive members and limiting domin-
ant speakers while trying to allow group dialogue to
ﬂow.36,39
In the second part, participants were presented with
a functioning mock-up of the DC interface imple-
mented on a tablet computer. The interface contained
a range of information types and options that could be
accessed and altered through a touch screen mechan-
ism. These data and preferences were not integrated to
the information management system of any actual bio-
bank but allowed participants to explore and play with
the features without concern about real-time conse-
quences. When it came to introducing the tablet, par-
ticipants were arranged into small groups of 23
persons each being given a tablet computer to interact
with. All members of the research team present parti-
cipated in this activity. They helped ensure that all
focus group participants spent time using the tablet.
The researcher could respond to questions and, occa-
sionally, prompt the participants to explore further
aspects of the interface. This section lasted approxi-
mately 20minutes, after which the whole group recon-
vened to discuss their perceptions of the DC interface.
The participants’ use of the DC interface was
intended to elicit two forms of responses. The ﬁrst,
not reported here, related to the speciﬁc instantiation
of the interface providing feedback to the system devel-
opers for how they might improve the usability of the
interface (e.g. by changing wording on the screens).
Second, by giving the study participants access to a
‘working’ implementation of DC, we sought to elicit
responses and reactions to the range of options for
communication and interaction beyond their previous
experiences of paper forms and broad consent. The
focus group method enabled individuals to discuss
their responses to the interface with each other, discuss-
ing the relevance of each feature but not necessarily
reaching consensus on which aspects were most or
least useful. Although not an explicit research aim,
allowing study participants to explore the DC interface
also resulted in them talking extensively about their
biobanking experience more generally.
Table 2. Recruitment and focus group characteristics. Response rates listed here are based on the number of individuals we were able to
recruit within the allocated time and whom we were able to assign to a pre-arranged focus group session.
Biobank
Recruitment Response Focus groups
Family members
included?
Letters
sent Targeting?
Number
recruited
Response
rate
Number
of groups
Size (persons)
per group
1 300 Previous survey
responders
17 5.7% 3 6; 8; 3 (participants
P1P17)
Yes
2 300 No 9 3% 2 4; 5 (participants
P18P26)
No
3 50 Patients at appropriate
treatment stage only
6 12% 2 inter-
views
1 focus
group
Interview 1: 2 people;
Interview 2: 1 person;
Focus group: 3 people
(participants P27P32)
Yes
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Data analysis
An audio recording was made of each focus group and
interview, with the explicit consent of all participants.
The recordings were transcribed by a professional tran-
scription service. These transcripts were independently
coded and then compared. The initial coding was used
to produce broad thematic codes based on issues iden-
tiﬁed from the literature. The individually coded tran-
scripts were compared and the coding frames discussed
until a consensus framework was developed. Examples
of thematic codes included ‘Recruitment’ to capture
discussions of participants’ experiences of being asked
to take part in the biobank, ‘Consent’ which was
intended to record attitudes and pronouncements on
the value of consent, or ‘digital divide’ for statements
relating to suggestions that diﬀerent age groups might
respond diﬀerently to digital technologies (especially
the DC interface). These are analyst’s categories
rather than participants’ categories. This coding frame-
work was then applied to the remainder of the tran-
scripts using manual coding and a ﬁnal review of all
coded transcripts for consistency was undertaken.
Findings
Opinions on consent and withdrawal
The study elicited participants’ views about existing
types of consent, especially broad consent, and learned
about their experiences as biobank donors. Across the
diﬀerent groups, participants presented a generally
positive view of the (broad) consents they had given
for the use of their samples and data and no participant
reported a current or anticipated desire to withdraw
from any of the biobanks they were involved with.
For some participants, consent was framed as an agree-
ment or contract that should not need revisiting; ‘once
I’ve given my consent then I’ve given my consent’
(Biobank 3, P29), and where donors had a responsibil-
ity to uphold their agreement: ‘I personally wouldn’t
sign up to do it if I thought I would need to withdraw
at any stage’ (Biobank 2, P19).
Others took a diﬀerent approach, regarding the deci-
sion to give consent as being safeguarded by the option
to withdraw from the biobank if necessary: ‘if you did
want to opt out at any point, you had that power to do
so’ (Biobank 3, P29). One group member described the
option of withdrawal as conferring a ‘feeling of conﬁ-
dence that you can, at any point, say ‘‘Actually, no’’’
(Biobank 2, P20). Additionally, a few focus group par-
ticipants demonstrated a signiﬁcant lack of understand-
ing of the implications of broad consent, claiming that
‘. . . it’s not like I’ve just given consent for anything’
(Biobank 2, P20) and ‘you can’t be expected to consent
to every future study that’s going to come along’
(Biobank 2, P22). However, in terms of their satisfac-
tion with one-oﬀ broad consent for biobanking the
ﬁndings from these focus groups are largely in line
with the ﬁndings of previous studies.7,17,18
Experiences of giving consent
Participants were asked to reﬂect on how they came to
donate tissue to a biobank. Where appropriate,
prompts were used to introduce speciﬁc discussion
around giving consent. Some group members reported
favourable experiences of giving consent:
It was very positive, [. . .] you had it in advance and then
when you turned up, they went through it and made
sure that you understood everything (Biobank 2, P21).
Whilst for others it was not a wholly negative experi-
ence, it was something ‘rather perfunctory’ (Biobank 3,
P29), simply ‘a piece of the bureaucracy that you have
to go through’ (Biobank 1, P3) and not an event that
was felt to create an ongoing relationship between par-
ticipant and biobank:
I remember a blue ﬂimsy paper that I remember sign-
ing, and I remember being told that my hip joint would
be taken [. . .] And like you I haven’t thought a thing
about it since (Biobank 1, P3).
One potential reason for this observation is the timing
of consent. This was particularly evident in groups
where participants had tissue excised as part of their
treatment and where consent giving was closely linked
to medical procedures. Receiving a diagnosis and being
told that surgery was required was described as ‘very
stressful’ and ‘emotional’ (Biobank 3, 28) and respond-
ents spoke of being ‘in a state of shock’ (Biobank 3,
P29) following the news. Donating excised tissue to the
biobank was portrayed very much as a secondary con-
cern at the time.
The reality of obtaining consent for research using a
paper-based system is that it must be done when
patients are in clinic as there is little opportunity to
contact people otherwise. Recruiting patients into
research during a visit to the clinic means that clinical
needs often eclipse research as a priority. For the
patients concerned this can be a stressful time and
may explain why some participants struggled to
remember the details of consent or recall a clear motiv-
ation for giving consent.
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Motivations and concerns
The motivations reported by study participants and
across groups for taking part in research include some
form of association with an existing group aﬀected by a
disease or condition as well as reciprocity in both cate-
gories identiﬁed by Nobile et al.16 Examples of ‘altru-
istic’ reciprocity as motivation include identiﬁcation of
research as ‘a very important part of medicine’
(Biobank 3, P29), to ‘beneﬁt future generations’
(Biobank 2, P22), and a desire to ‘give a little bit
back’ (Biobank 1, P32), and to add to ‘the greater
good’ (Biobank 2, P23).
These motivations appear to be clearly linked with a
conception of biomedical research as clear ‘good’  a
positive force for progress and the alleviation of suﬀer-
ing. This understanding is reﬂected in the reported sat-
isfaction with broad consent and in the diﬃculties
participants experienced when trying to conceive of a
circumstance in which someone would want to exercise
the option to withdraw from a biobank: ‘if it’s all for
research and promote health and the correct medicines,
I can’t see any reason why you would want to pull out’
(Biobank 2, P23). This was supported by another focus
group participant who opined:
So, anything I can give them [. . .] is for my beneﬁt as
much as for my children’s, or my grandchildren’s bene-
ﬁt. So, I think it would very naı¨ve if they withdrew,
personally (Biobank 1, P14).
Although, for the reasons outlined above, none of the
participants anticipated withdrawing from the biobank,
being asked for consent and oﬀered the option of with-
drawal were largely seen as options that were ‘polite’ or
reassuring. Not giving consent, or withdrawing it at a
later date were largely presented as something that
might be required only by ‘others’ such as people
with unspeciﬁed ‘religious or cultural’ motivations.
One participant identiﬁed a diﬀerent function of
being oﬀered the option of withdrawal  as a (sym-
bolic) means of demonstrating respect for donors as
people: ‘I can’t see it being used, but I think it, I
think you have to put it in to make people feel that
they are being helpful rather than just simply tools
being used’ (Biobank 1, P17).
As noted above, a key beneﬁt of the focus group
approach is the evolving discussion between partici-
pants. In the course of the group discussions speciﬁc
concerns about future uses of samples or data emerged
that were often oﬀset by expressions of the trustworthi-
ness of institutions and the desirability of research. The
most commonly cited trusted institutions were the
National Health Service and local universities.
Medical expertise, for example ‘high level doctors’
(Biobank 3, P29), was also reported as a source of
trust, while ‘industry’ and insurance companies were
raised as types of organisations inspiring suspicion.
This is similar to phenomena identiﬁed by Hobbs in
previous studies of UK and German biobanks,14
where potential dis-beneﬁts to biobank participants
such as privacy risks were balanced by the perceived
beneﬁts for wider communities such as particular
patient populations or even the ‘general good’.
Some common concerns were raised about the secur-
ity of personal medical data, the possibility of ﬁndings
(especially from genetic research) that the respondents
would not want to know, and recognition that ‘there is
potentially a risk that your samples or your data could
be used for something perhaps you’re not happy
[about]’ (Biobank 2, P21).
While we did not explicitly ask participants about
their motivation for attending the focus groups, several
suggested that they were similar to their reasons for
taking part in biobank research, speciﬁcally that:
I’m giving back a little bit perhaps to the NHS for all
the stuﬀ I’ve had out of it. (Biobank 1, P5).
and that it would be an ‘interesting afternoon’ and
‘something diﬀerent to do’ (Biobank 1, P5). It was
also apparent that for a number of participants, the
focus group invitation letter was their ﬁrst reminder
that they had signed up to take part in the biobank,
as they ‘haven’t thought any more about it until I
received your letters’ (Biobank 1, P2).
Participants didn’t appear to have speciﬁc impres-
sions about dynamic consent before joining the
focus group, which provided an opportunity to ﬁnd
out more about an area they had previously ‘not
really thought about’ (Biobank 3, P29). As one partici-
pant described:
I’m perfectly happy to be here and talk but I’m still, to
a degree, in the dark as to what I’m doing here. Now, I
don’t mind being here, but I don’t quite know what I’m
helping you with (Biobank 1, P17).
But several suggested they thought it was a relevant
topic in general:
When I got your letter it was quite interesting to see
that this was, you know, quite a serious area of research
and that you were, you know, clearly thinking about
patient involvement on a level that I’d not really
thought about (Biobank 3, P29).
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Responses to the dynamic consent interface
The DC interface that study participants used included
the option to ‘log in’ to a personal account and not only
revisit individual consent choices, but also to access
information on sample projects that they had ‘con-
sented to’, including descriptions of the project aims,
the institutions involved, project duration and broader
context of the disease conditions involved. It also
described how the research might help in treatment or
prevention and how this could allow for tailored par-
ticipant engagement depending on the needs and cap-
abilities of the research programme.
This function of the DC interface prompted consid-
erable discussion across groups. For a number of par-
ticipants, this property of the system was regarded as a
potential improvement on their current experiences of
having given consent to a biobank. This option was
regarded as helpful both for addressing the timing of
consent:
So that you are going into these [situations of being
asked for consent] completely with your eyes open,
and perhaps not under the stress of [. . .] a big meeting
when you’re discussing the actual surgery and so on
(Biobank 3, P29),
and for helping others who had little recollection of
what they had agreed to, or had ‘absolutely no idea
what research is being done on whatever was sent oﬀ
to the biobank’ (Biobank 3, P29). The DC interface
does not remove the requirement for initial face-to-
face consent, but it does allow details to be revisited
and checked at a later date: ‘if we can log on online
back to our person[al] information we can double-
check that we ticked that box to say ‘‘Yes’’’ (Biobank
2, P24).
Although many participants were unaware of what
biobanking research entails in practice, this did not
appear to be the result of a lack of interest. Many
participants agreed that they would be interested to
know how research was progressing, and indeed that
as a donor: ‘[y]ou should know what’s going on’
(Biobank 1, P3). A participation information sheet
oﬀers little opportunity to provide detailed informa-
tion in answer to these broader questions, not least
because it is often produced and approved at an
early stage of research when few results are available.
Although some biobanks provide updates and news-
letters to inform patients of how research is progress-
ing this often provides generic, rather than
personalised information. Focus group participants
in this study welcomed an opportunity for more spe-
ciﬁc information ‘about what the actual research was
and what the end result of the research is meant to be’
(Biobank 1, P6) and ultimately to know whether their
contribution ‘helped to answer a question’ (Biobank 2,
P22).
The contribution research makes to medical pro-
gress, was cited as a motivation of biobank partici-
pants, as one participant expressed:
I think we all have a belief in research, because without
research and experimentation you don’t get any further
forward (Biobank 1, P11).
It is perhaps not surprising that many would like to
have more information on the outcomes of research,
and their speciﬁc role in this progress:
It would be interesting to know if they scored a hit with
your . . . you know, something you’d contributed had
helped take something a bit further forward (Biobank
1, P3).
This can be considered an additional form of more per-
sonal reciprocity between biobanks and participants,14
and supports the contention that donor endorsement of
broad consent does not necessarily constitute a rejec-
tion of ongoing interest in how their samples and data
are used.10
Benefits of tailored information
Focus group participants also recognised that, within
groups, diﬀerent people were approaching participation
from very diﬀerent viewpoints, and that they ‘all have
[their] own interests and [their] own scope of know-
ledge’ (Biobank 1, P15). Accordingly it was recognised
that the levels and type of information accessible
through a DC interface would be best tailored to indi-
vidual needs, as diﬀerent users ‘could access it at diﬀer-
ent levels, depending on where they’re coming from’
(Biobank 3, P29).
The digital nature of the DC interface also allows for
the deployment of a variety of media to provide infor-
mation in diﬀerent ways. This was recognised as an
advantage by some participants:
There’s a place for [videos] and. . . a place for the writ-
ten word and some suit some people, and some will suit
the others (Biobank 1, P17).
The DC interface, by presenting a personalised proﬁle
that would allow participants to select the sort of infor-
mation they wished to receive alongside updates on
their data and samples would go a long way towards
satisfying participants’ desire to be better informed and
would play an important role in making biobank con-
sent more meaningfully informed.
8 DIGITAL HEALTH
Promoting research participation
Another feature of the DC interface was the inclusion
of information about other biobank research studies
that the participants might wish to participate in.
Several focus group participants welcomed enhanced
communication and information about such opportu-
nities to put themselves forward for other research
projects:
I think it’s a way of, you know, encouraging, you
know, participation in trials (Biobank 3, P30).
By promoting ongoing engagement beyond the initial
consent procedure by ‘being able to tick a box to sign
up for something’ and ‘being able to access other bio-
bank studies’ (Biobank 2, P24), donor engagement with
the biobank can be transformed into an ongoing part-
nership for engaging in future research.
If it was a little box I can tick to say ‘‘Yes, I’m happy
for you to pass on my biobank information to [speciﬁc]
research project[s] because I’d be interested in getting
involved’’ that’s great (Biobank 2, P26).
Given that the costs of re-contact are often cited as one
of the major challenges for biobanking research,3 there
are clear beneﬁts oﬀered by the DC interface that
allows patients to drive their own participation, rather
than placing the onus on the research team to drum up
support.32
Towards Engagement 2.0
Whilst the DC approach relating to providing, review-
ing and changing consent preferences, was largely wel-
comed by study participants, we were particularly
struck by the interest that was sparked by the possibil-
ity to use the interface to transform engagement, which
is a signiﬁcantly diﬀerent function of the DC interface
than the granular consent choices. The opportunities
for more dynamic approaches to giving and revoking
consent thus became the vehicle for introducing more
diverse approaches to engaging with biobanks,
approaches that echo the characteristics and motiv-
ations for Web 2.0.
The central beneﬁts that were highlighted as import-
ant to the biobank participants involved in these focus
groups were:
. the opportunity to improve on the timing of con-
sent, and enable participants to reﬂect and review
consent decisions over time including having a
record of previous consent decisions available
electronically;
. the opportunity to hear about the research their data
and samples have contributed to, and to receive
updates on further projects;
. the ability to have greater control over their involve-
ment and to feed more directly into the research
process through interactive engagement;
. and the chance to receive tailored information, in a
variety of media, to suit the interests and under-
standing of the individual.
We suggest that these ﬁve characteristics, namely
timing, research participation, autonomy, consent and
knowledge (TRACKs), form the central tenets of an
‘Engagement 2.0’ approach, and characterise what is
meant by DC, not just as a new technical solution, but a
system-wide behaviour change. Additional characteristics
are likely to arise as further experience with Engagement
2.0 occurs and participants request further interactivity
options from the biobanks they are working with.
This provides a more nuanced solution to enable
reciprocity to work in practice and to suggest some
ideas of the kind and formats of information that
people would like provided. It moves away from
polarised arguments about broad vs repeat consent
and about how much information should be included
on participant information sheets to make consent ade-
quately informed, by allowing participants to make
these decisions for themselves, about how engaged
they wish to be, and which information they need to
access to decide whether or not to take part.
Table 3 outlines the key features (TRACKs) of
Engagement 2.0, indicating how they diﬀer from more
conventional (Web 1.0) approaches. Each feature is
illustrated with data from the study.
Study limitations
This was a local preliminary study of the DC interface
with a small sample size. The response rates to the
recruitment eﬀorts were low so that everyone who vol-
unteered to take part in the study was accepted. There
was no opportunity to select participants to ensure a
representative sample on the grounds of age, gender or
other criteria. There were no participants from BME
groups. The main limitation of this study is that as
volunteers the participants likely represent a self-select-
ing group who were already motivated to take part in
research in general and are therefore also more likely
than other biobank donors or the general public to be
in favour of learning more about biobanking and being
engaged through ongoing communication with a bio-
bank. It is also possible that the participants’ attitudes
to research and to the DC interface were aﬀected by a
desire to appear morally virtuous to members of the
research team and to each other. However, they were
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not deterred from discussing other potentially problem-
atic behaviours, such as admitting that they could not
remember the details of giving consent to donate their
tissue to the biobank.
Conclusions
The aims of this study were to understand the views of
biobank participants about their experience of being
involved in a biobank, and elicit how they reacted to
the opportunities that the DC approach oﬀered and
whether it would increase their conﬁdence and trust
in their involvement with biobanks. Participants were
shown a demonstration of the DC system that oﬀers a
more dynamic, Web 2.0 interface for managing their
consent preferences as well as oﬀering access to bio-
bank related sources, which we are calling an
Engagement 2.0 approach.
Table 3. The TRACKs of Engagement 2.0.
Feature Engagement 1.0 Engagement 2.0 Engagement 2.0 examples from the study
Timing Linear flow, one time decisions Iterative processes supported,
ability to review and revise
decisions
‘I didn’t realise that I was involved, but I remember
when I had the op you took a whole lot of extra blood
samples’ (Biobank 1, P1)
‘I was asked to take part in a study, it was not going
to hurt or cost, so I thought ‘why not’, it wasn’t a
deep, deeply-thought decision, it was just ‘Yeah, all
right, why not’, you know, if something helps, I’m
quite happy to do that, I didn’t consider for one
moment the long-term benefits if you like, I was just
happy to take part and it’s just sort of carried on’
(Biobank 2, P23)
Research
participation
Flyers and leaflets
Conversation from consultant to
participant
Option to search for participation
opportunities
Dialogue with researchers
Notification of opportunities
‘Yes, it is something I’ve mentioned before, I would
like to more of what you are doing, but I would like to
know in fairly lay terms’ (Biobank 1, P17)
‘The more people you get, the more people you’ll get,
people will talk to people’ (Biobank 2, P20)
Autonomy Passive Active, empowered, ongoing ‘It makes it more sort of dynamic, and interactive isn’t
it the current system where we sit and wait to hear
something’ (Biobank 2, P25)
‘It’s, you know, looking up things about myself and
my cancer and so on, I’ve not wanted to do, but
possibly looking at what has happened to what I’ve
donated is less pertinent to actually my actual cancer
and therefore might be much more interesting to
read’ (Biobank 3, P29)
Consent Paper based, broad Dynamic ‘At the moment, we’re, you know, we’re giving our
consents and then go away and we don’t think any
more about it’ (Biobank 1, P5)
‘I think it was this point in my consent choices that
was the only thing that had occurred to me in
advance, when I got this was to include in here some
way of differentiating between sort of academic
research and more commercial research’ (Biobank 3,
P30)
Knowledge Biobank specific leaflets and
resources
Participant specific information,
opportunities to share experiences
and questions with community of
participants
‘I suppose you’d you want an email alert to say ‘‘Just
used your sample’’ and then you can log in and see
what it’s being used for. . .’ (Biobank 2, P21)
‘At the time I wasn’t really concerned as to who was
getting access to it and what they were doing, but I
suppose in the light of your research, it might be
quite nice to know if there’s an end result. But
monitoring what’s happening along the way, you
know, I hadn’t really, you know, thought of’ (Biobank
3, P29)
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Biobank participants in our study are supportive of
biobank research, and were reasonably happy with the
method for being consented into the biobank  given
that they had all agreed to be recruited into the bio-
bank, and then to take part in our focus groups, this
was not an unexpected ﬁnding. It demonstrated the
considerable trust they had in the clinical staﬀ that
were treating them, which in turn had encouraged
them to become involved in research. There was also
evidence that this group were altruistic and supportive
of research which they saw as a way of helping their
families and subsequent generations.
For this group, it was not an issue to be asked for a
broad consent to have samples deposited into a biobank
for many diﬀerent research purposes by the clinical staﬀ
that they trusted. However, they considered that obtain-
ing consent was a mandatory requirement, and individ-
uals should always be asked to be involved in research
and to be recruited into a biobank. When presented with
the possibility of being able to change their consent pref-
erences through the DC interface, they could imagine
that others might ﬁnd the consent choices useful  at
the very least being able to have a choice was seen as a
courtesy, and demonstrated a more involved role in the
research project. It was also essential to have the ability
to withdraw at any time even though they felt they per-
sonally would never have the need to exercise this
option, although some had not fully appreciated what
they had consented to given the close timings between
surgery and participation in the biobank.
When presented with the Web 2.0 functionality that
DC enabled, biobank participants were enthusiastic
about the potential to know more about the research
process and how their samples were being used. They
could understand the beneﬁts of being able to get more
information if they needed it, rather than only having a
paper information sheet. They responded positively to
being able to check what they have agreed to, after
being recruited in a busy clinical setting and also to
specifying how and when they received information.
This was regarded as a way to acknowledge the contri-
bution that they had made to research by donating
their samples, but also to know about ways to
become enrolled in other research activities. They
regarded these possibilities as oﬀering more in terms
of information than they have received when they had
been enrolled in the biobank.
This study has ﬁrstly demonstrated that research
participants we studied would welcome more informa-
tion through an online interface. However, perhaps
more importantly, their suggestions for how the DC
interface could be developed show an appetite for
greater interaction which can be seen as the beginnings
of what we have described as Engagement 2.0. This
study provides the foundation for other studies
exploring the use of Web 2.0 technologies in engage-
ment, but also has provided the basis for development
of the DC interface in biobanking.
The next stage will be to fully test the DC interface
within a research study to explore the downstream impli-
cations of both the consent and engagement functions,
and the realities of the model in practice. Existing biobank
resource constraints (ﬁnancial, technological, staﬃng)
may limit the kinds of Engagement 2.0 facilities oﬀered
to participants. For example, study design considerations
may limit the range of consent revocation options avail-
able to participants and, unless explicitly costed, there
might only be limited staﬀ time that could be used to
discuss research participation options with researchers.
Similarly, there may need to be a culture change for this
new technology and approach to engagement to be fully
adopted and integrated into practice to ensure that par-
ticipant speciﬁc information and opportunities to share
experiences as an online community of equals are built
and maintained. How this ﬁts with current research prac-
tices, and where there are improvements and eﬃciencies
that can be made through the use of DC will need to be
fully explored within a research setting.
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